By Chloe Ackaert, Jana Schockaert, Aurelie Mazy, Martijn Vlaming, and Sofie Pattyn
Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024

Bispecifics targeting multiple antigens or epitopes have been showing great promise for treatment of cancer. However, managing unwanted immunogenicity has become a challenge in the development cycle of these promising therapeutics as there is a trend towards higher unwanted immune responses compared with classical monoclonal antibodies. MHC-associated peptide proteomics (MAPPS) assays enable the precise identification of all regions of a protein that make evoke an immune response.

Complete the form below to access this scientific poster.